FDA Actions in Brief April 2012
Recent FDA Approvals (through April 2012) related to (Johnson & Johnson, AstraZeneca, Affymax, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Avioq, Hope Pharmaceuticals, Novo Nordisk, Avid Radiopharmaceuticals)
Etravirine (Intelence, Johnson & Johnson) was approved for the treatment of HIV-1 in children aged 6 years to younger than 18 years who have taken other therapies but whose infection has become resistant to treatment.
Metoprolol succinate extended release/hydrochlorothiazide (Dutoprol, AstraZeneca) tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of Toprol-XL (metoprolol succinate) plus a low-dose diuretic for the treatment of high blood pressure.
Peginesatide (Omontys, Affymax and Takeda Pharmaceutical) was approved for the treatment of anemia in adult dialysis patients who have chronic kidney disease.
Test (Avioq HTLV-I/II Microelisa System, Avioq) was approved to detect antibodies to viruses in donors of human blood and blood components that are associated with several diseases, including some forms of leukemia and neurologic diseases was approved.
Sodium Nitrite Injection (Hope Pharmaceuticals) for sequential use with sodium thiosulfate for the treatment of cyanide poisoning that is judged to be life-threatening.
Insulin detemir [rDNA origin] (Levemir, Novo Nordisk) was approved for a pregnancy category B classification, meaning that when used by pregnant women, the insulin did not increase the risk of harm to fetuses.
Florbetapir F 18 Injection (Amyvid, Avid Radiopharmaceuticals) was approved for Positron Emission Tomography (PET) imaging of the brain in adults who are being evaluated for Alzheimer's and other causes of cognitive decline.
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
